Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). See package insert for complete information.

IDACIO is a tumor necrosis factor (TNF) blocker indicated for:
• Rheumatoid Arthritis (RA)
• Juvenile Idiopathic Arthritis (JIA)
• Psoriatic Arthritis (PsA)
• Ankylosing Spondylitis (AS)
• Crohn’s Disease (CD)
• Ulcerative Colitis
• Plaque Psoriasis (Ps) See package insert for complete information.

Injection:
• Single-dose prefilled pen (IDACIO Pen): 40 mg/0.8 mL 
• Single-dose prefilled glass syringe: 40 mg/0.8 mL 

Most common adverse reactions (>10%) are infections (e.g. upper respiratory, sinusitis), injection site reactions, headache and rash.

None

• Serious infections: Do not start IDACIO during an active infection. If an infection develops, monitor carefully, and stop IDACIO if infection becomes serious.
• Invasive fungal infections: For patients who develop a systemic illness on IDACIO, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic.
• Malignancies: Incidence of malignancies was greater in adalimumab-treated patients than in controls.
• Anaphylaxis or serious hypersensitivity reactions may occur.
• Hepatitis B virus reactivation: Monitor HBV carriers during and several months after therapy. If reactivation occurs, stop IDACIO and begin antiviral therapy.
• Demyelinating disease: Exacerbation or new onset, may occur.
• Cytopenias, pancytopenia: Advise patients to seek immediate medical attention if symptoms develop and consider stopping IDACIO.
• Heart failure: Worsening or new onset, may occur.
• Lupus-like syndrome: Stop IDA